Dynamics of vessel wall changes following the implantation of the absorb everolimus-eluting bioresorbable vascular scaffold: a multi-imaging modality study at 6, 12, 24 and 36 months.
about
Bioresorbable scaffolds for percutaneous coronary interventionsBioresorbable scaffolds: a new paradigm in percutaneous coronary interventionThe Safety and Efficacy of Absorb Bioresorbable Vascular Scaffold: A Systematic ReviewBioresorbable Scaffolds: Current Evidences in the Treatment of Coronary Artery DiseaseEchogenicity as a surrogate for bioresorbable everolimus-eluting scaffold degradation: analysis at 1-, 3-, 6-, 12- 18, 24-, 30-, 36- and 42-month follow-up in a porcine model.Everolimus-Eluting Bioresorbable Vascular Scaffold in Real World Practice - A Single Center Experience.Appropriate use of bioresorbable vascular scaffolds in percutaneous coronary interventions: a recommendation from experienced users : A position statement on the use of bioresorbable vascular scaffolds in the Netherlands.Neointimal coverage and late apposition of everolimus-eluting bioresorbable scaffolds implanted in the acute phase of myocardial infarction: OCT data from the PRAGUE-19 study.Angiographic and optical coherence tomography insights into bioresorbable scaffold thrombosis: single-center experienceClinical Outcomes of Bioresorbable Scaffold in Coronary Artery Disease: A Systematic Literature Review.Role of invasive imaging in acute and long-term assessment of bioresorbable scaffold technology.Everolimus-eluting bioresorbable stent vs. durable polymer everolimus-eluting metallic stent in patients with ST-segment elevation myocardial infarction: results of the randomized ABSORB ST-segment elevation myocardial infarction-TROFI II trial.Sustained safety and performance of the second-generation drug-eluting absorbable metal scaffold in patients with de novo coronary lesions: 12-month clinical results and angiographic findings of the BIOSOLVE-II first-in-man trial.Current and future perspectives on drug-eluting bioresorbable coronary scaffolds.Histopathology of vascular response to drug-eluting stents: an insight from human autopsy into daily practice.Bioresorbable scaffolds for the treatment of coronary artery disease: current status and future perspective."Leaving nothing behind": is the bioresorbable vascular scaffold a new hope for patients with coronary artery disease?Coronary artery stents: advances in technology.Long-term serial non-invasive multislice computed tomography angiography with functional evaluation after coronary implantation of a bioresorbable everolimus-eluting scaffold: the ABSORB cohort B MSCT substudy.Causes, assessment, and treatment of stent thrombosis--intravascular imaging insights.Alternative stents in ST-segment elevation myocardial infarction: improving the efficacy of primary percutaneous coronary intervention.The ABSORB bioresorbable vascular scaffold: A novel, fully resorbable drug-eluting stent: Current concepts and overview of clinical evidence.Differential aspects between cobalt-chromium everolimus drug-eluting stent and Absorb everolimus bioresorbable vascular scaffold: from bench to clinical use.Biomechanical Challenges to Polymeric Biodegradable Stents.Potential therapeutic effects of mTOR inhibition in atherosclerosis.From drug eluting stents to bioresorbable scaffolds; to new horizons in PCI.Bioresorbable Scaffolds for Atheroregression: Understanding of Transient ScaffoldingBioresorbable drug-eluting scaffolds for treatment of vascular disease.Optimisation of percutaneous coronary intervention: indispensables for bioresorbable scaffolds.Bioresorbable Polymers and Stent Devices.Bioresorbable vascular scaffolds - basic concepts and clinical outcome.Paving the way to a bioresorbable technology: Development of the absorb BRS program.Bioresorbable vascular scaffolds for the treatment of coronary artery disease: Clinical outcomes from randomized controlled trials.Expanded clinical use of everolimus eluting bioresorbable vascular scaffolds for treatment of coronary artery disease.Angiographic and clinical outcomes of patients treated with everolimus-eluting bioresorbable stents in routine clinical practice: Results of the ISAR-ABSORB registry.A Computational Framework to Model Degradation of Biocorrodible Metal Stents Using an Implicit Finite Element Solver.A 12-month angiographic and optical coherence tomography follow-up after bioresorbable vascular scaffold implantation in patients with ST-segment elevation myocardial infarction.Neoatherosclerosis development following bioresorbable vascular scaffold implantation in diabetic and non-diabetic swine.Implantation of everolimus-eluting bioresorbable scaffolds in a diabetic all-comers population.Current status of clinically available bioresorbable scaffolds in percutaneous coronary interventions.
P2860
Q21972838-A237BEA7-E9D5-41D5-860A-926A50AF47E8Q26766579-6EC24D84-7B34-4970-B594-4F5E152CE2BBQ26782136-07084C2E-5D64-477A-96DF-772062483868Q28076491-A2094A2B-8380-412E-91A3-4146AD90D586Q30415979-04C0134B-5496-490E-8EC0-6BE3CC89803EQ33729836-4588E229-3BDB-42D9-80BB-41EFBE851D3FQ35155123-FFC15285-FC7E-4DF2-8F79-7DA28970BB00Q35610359-BF8DD61B-CD8B-45AB-AF03-08B4F74EF0DEQ35787354-1BDF72A4-38B9-426D-984B-960B88291896Q35884429-50730EB5-9EBA-4C6B-ADD1-FFB128BA4E1AQ36178330-2598593A-3560-4473-B6F2-75C0B3A9F4C0Q36460858-F92A192C-BCC8-481F-91AF-6646E4F414C2Q37285036-734FA4D7-4B53-41EC-9962-5D30C7C8EACEQ38224405-0F4D4BBD-C1F4-4444-8A12-8150EA710A54Q38235226-A23FC89C-21F1-49AE-9FD1-FC0ADB0F1A4FQ38236449-46A9892E-4552-442C-8DB2-5D3BD02116BBQ38285660-520BF751-AF09-4A12-B30A-BBEE1F9797C2Q38287152-C466E5A9-ABBE-4C8E-BA8C-5F448E59416FQ38379161-5102D541-6728-4C06-B3DD-A631ADCC6912Q38381419-30A9214E-C43D-4E05-A8F4-1727E4DE96C1Q38506261-EC9CAED7-0A6E-40EA-9029-FD1A521F2D4DQ38589504-2B961E9C-1EDE-4E26-B1F5-EDEE8C51CAAAQ38592121-E1C35272-8459-4DE2-884C-B8AA1EBEEEC7Q38606597-C62CA517-B10A-49ED-A05A-8518969F79BEQ38628797-5703480D-E2D5-4B28-AEA7-7DD53BFD2A86Q38702003-D570418B-A571-4406-8829-3E5C203D7FF2Q38714351-04B734D9-546F-4997-91B7-872DD92F9AB8Q38728978-6671889A-DB77-4DB9-A038-3CC2BF8A1A68Q38885397-BE78AEEC-44E9-4DFC-AA35-9801F6D38FAFQ38919254-690EAA8B-BBDF-4543-BA8E-1BCF406DF25EQ38967027-80B00C54-DA07-4217-B9A5-7ED5A1EA7A08Q38995000-2F39C0F9-BBD9-4567-BF83-7DF8FD6FA54CQ38995006-DFD0DAE7-6357-4D89-A26B-BC126573CAE6Q39146266-D24F6118-0E34-4B0B-89C5-3E3FF163990EQ40167885-15921FE9-A5F4-4DF1-82A8-15788F6E132DQ40172203-C1D10E0B-D445-4546-A9C1-6347BE0F9D44Q40898662-A1CA88C3-BF87-48F6-B24A-20DF1698319EQ41230267-9289C3E6-1C45-4D26-BD12-35AA5F8CE4BDQ41486976-3E5B4578-73A4-4F1A-A355-E35095034031Q41875719-A5B5F644-AB62-482E-8977-AD0DC5D20211
P2860
Dynamics of vessel wall changes following the implantation of the absorb everolimus-eluting bioresorbable vascular scaffold: a multi-imaging modality study at 6, 12, 24 and 36 months.
description
2014 nî lūn-bûn
@nan
2014 թուականի Մարտին հրատարակուած գիտական յօդուած
@hyw
2014 թվականի մարտին հրատարակված գիտական հոդված
@hy
2014年の論文
@ja
2014年論文
@yue
2014年論文
@zh-hant
2014年論文
@zh-hk
2014年論文
@zh-mo
2014年論文
@zh-tw
2014年论文
@wuu
name
Dynamics of vessel wall change ...... dy at 6, 12, 24 and 36 months.
@ast
Dynamics of vessel wall change ...... dy at 6, 12, 24 and 36 months.
@en
Dynamics of vessel wall change ...... dy at 6, 12, 24 and 36 months.
@nl
type
label
Dynamics of vessel wall change ...... dy at 6, 12, 24 and 36 months.
@ast
Dynamics of vessel wall change ...... dy at 6, 12, 24 and 36 months.
@en
Dynamics of vessel wall change ...... dy at 6, 12, 24 and 36 months.
@nl
prefLabel
Dynamics of vessel wall change ...... dy at 6, 12, 24 and 36 months.
@ast
Dynamics of vessel wall change ...... dy at 6, 12, 24 and 36 months.
@en
Dynamics of vessel wall change ...... dy at 6, 12, 24 and 36 months.
@nl
P2093
P50
P356
P1476
Dynamics of vessel wall change ...... dy at 6, 12, 24 and 36 months.
@en
P2093
Bernard Chevalier
Bernard de Bruyne
Cecile Dorange
Dougal McClean
Hector M Garcia-Garcia
Ian Meredith
Jacques Koolen
John A Ormiston
Karine Miquel Hebert
Leif Thuesen
P304
P356
10.4244/EIJV9I11A217
P577
2014-03-01T00:00:00Z